中国全科医学2025，Vol.28Issue(21)：2679-2685,7.DOI:10.12114/j.issn.1007-9572.2024.0484
Danuglipron与Orforglipron治疗2型糖尿病疗效及安全性的Meta分析
Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus:a Meta-analysis
摘要
Abstract
Background Currently,there are several glucagon-like peptide-1 receptor agonists(GLP-1RAs)used for the treatment of type 2 diabetes(T2DM),but most are administered by subcutaneous injection,which reduces patient compliance.Danuglipron and Orforglipron are novel oral small molecule GLP-1RAs,which may become a strong choice for hypoglycemic drugs in the future.Objective To systematically evaluate the efficacy and safety of Danuglipron and Orforglipron in the treatment of T2DM.Methods A computerized search was performed on several authoritative databases,including PubMed,Embase,Cochrane Library,Web of Science,SinoMed,CNKI,Wanfang Data,and VIP databases.Randomized controlled trials(RCTs)comparing the efficacy and safety of Danuglipron or Orforglipron(test group)and placebo(control group)for the treatment of T2DM were collected,and the time frame for searching were all from the inception of the databases to May 2024.Screening was conducted based on pre-defined inclusion and exclusion criteria,and the quality of the screened literature was evaluated,the data were meta-analyzed using RevMan 5.4 software.Results A total of 6 studies were included in the analysis.The results indicated that in terms of efficacy,compared to the placebo group,the Danuglipron/Orforglipron group showed a reduction in glycosylated hemoglobin(HbA1c)(MD=-1.04,95%CI=-1.36 to-0.73,P<0.01)levels,fasting plasma glucose(FPG)(MD=-1.88,95%CI=-2.53 to-1.23,P<0.01)levels,and an increase in fasting plasma insulin(FPI)(MD=4.68,95%CI=2.42 to 6.95,P<0.01)levels.However,there was no statistically significant difference between the two groups in terms of weight reduction(MD=-4.00,95%CI=-10.14 to 2.15,P=0.20).Regarding safety,compared to the placebo group,the Danuglipron/Orforglipron group had increased rates of nausea(OR=7.85,95%CI=4.25 to 14.50,P<0.01),vomiting OR=9.45,95%CI=4.19 to 21.31,P<0.01),diarrhea(OR=1.96,95%CI=1.13 to 3.39,P=0.02),decreased appetite OR=4.56,95%CI=1.75 to 11.91,P<0.01),indigestion(OR=3.35,95%CI=1.54 to 7.32,P<0.01),belching OR=4.79,95%CI=1.13 to 20.23,P=0.03),constipation(OR=3.45,95%CI=1.24 to 9.56,P=0.02),and overall gastrointestinal adverse reactions(OR=5.37,95%CI=3.32 to 8.69,P<0.01).And there was no statistically significant difference in the occurrence rates of bloating(OR=2.67,95%CI=0.72 to 9.86,P=0.14)and headache(OR=0.73,95%CI=0.37 to 1.42,P=0.35)symptoms.Conclusions Oral administration of GLP-1 RAs Danuglipron and Orforglipron can effectively reduce the levels of HbA1c and FPG,also increase the levels of FPI and the incidence of nausea,vomiting,diarrhea,decreased appetite,dyspepsia,belching,constipation and total gastrointestinal adverse reactions,but have no effect on the incidence of abdominal distension and headache.关键词
糖尿病,2 型/Danuglipron/Orforglipron/循证医学/疗效/安全性/治疗结果/Meta分析Key words
Diabetes mellitus,type 2/Danuglipron/Orforglipron/Evidence-based medicine/Efficacy/Safety/Treatment outcome/Meta-analysis分类
医药卫生引用本文复制引用
马盼盼,王思静,游娜,丁大法,鲁一兵..Danuglipron与Orforglipron治疗2型糖尿病疗效及安全性的Meta分析[J].中国全科医学,2025,28(21):2679-2685,7.基金项目
江苏省卫生健康委科研项目(ZDB2020034) （ZDB2020034）
